Earnings call
Lupin Q1 FY27 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company expects its U.S. business to be in the USD 1.1 billion to USD 1.2 billion range for the full year, aided by growth in base business, injectable launches, and Pegfilgrastim contribution offsetting additional competition in Mirabegron and Tolvaptan during the year. Total revenues from operations exceeded INR 8,000 crores and its EBITDA exceeded INR 2,400 crores in Q1FY27, both first-time records. Albuterol market share was 16%, and the market had stabilized based on the supply situations from different competitors. Chronic segment accounted for around 67% of its portfolio in Q1FY27, up from around 65% in FY26, and the company targets increasing that share to 70% in the next five years. Operating Working Capital was INR 8,260 crores as of 30 June '26, compared with INR 7,132 crores as of 31 March '26, representing 90 days of net working capital compared with 87 days recorded earlier.
The numbers management gave
Results
- Total revenues from operations exceeded INR 8,000 crores and its EBITDA exceeded INR 2,400 crores in Q1FY27, both first-time records.
Show source
We are delighted to announce a record quarter with total revenues from operations and EBITDA exceeding INR 8,000 crores and INR 2,400 crores, respectively, for the first time in our history.
- The company recorded its 16th consecutive quarter of YoY growth in Q1FY27.
Show source
This quarter also marks a record 16 th consecutive quarter of YoY growth for the company.
- Ex-U.S. organic revenue grew 20% plus YoY in Q1FY27, with strong double-digit growth in India, Other Developed Markets, and Other Emerging Markets.
Show source
While the U.S. has obviously had an exceptional contribution to this performance, I would like to highlight that the ex -U.S. organic revenue growth for the company has been a strong 20% plus YoY and a strong double -digit growth in all our key markets, incl uding India, Other Developed Markets, and Other Emerging Markets.
- India business grew 13.9% YoY in Q1FY27, while its core prescription business grew 15.1%, representing 1.1x growth against IPM.
Show source
Coming to India, our India business has grown 13.9% YoY in the quarter with the core prescription business growing 15.1%, representing a 1.1x growth against IPM.
- Volume growth was 6.1% in Q1FY27, and its chronic share in the mix increased to around 67% from around 65% in FY26.
Show source
Volume growth was strong at 6.1% during the quarter.
- Anti-Diabetes segment grew 1.8x category growth and its Cardiac segment grew 1.2x category growth in Q1FY27.
Show source
Page 2 of 17 August 7, 2026 Most of our key therapy areas outperformed the respective market growth with Anti-Diabetes segment and Cardiac segment growing 1.8x and 1.2x the category growth.
Show 32 more statements
Results
- U.S. business grew 43% YoY, India prescriptions grew 15.1% YoY, Other Developed Markets grew 48%, Emerging Markets grew 52% YoY, and GIB business grew 40% YoY in Q1FY27. Lupin Limited’s core prescription business grew 15.1% YoY in Q1FY27 against IPM growth of 13.5%, translating to 1.1x IPM growth.
Show source
Sales grew 48% YoY in the quarter.
- European business grew 83% YoY in Q1FY27.
Show source
Our European business continued a strong momentum with 83% growth YoY.
- Emerging Markets recorded sales of INR 990 crores and 52% YoY growth in Q1FY27, led by Brazil, South Africa, and Philippines.
Show source
Emerging Markets delivered an impressive 52% YoY growth, led by Brazil, South Africa, and Philippines.
- Brazil business grew 117% YoY in local currency during Q1, driven by successful commercialization of Dapagliflozin and launch of Empagliflozin.
Show source
Brazil continued the strong momentum of the last four quarters, growing 117% YoY in local currency during Q1, driven by successful commercialization of Dapagliflozin and launch of Empagliflozin.
- Total revenue from operations grew 32% YoY to INR 8,277 crores and EBITDA excluding forex and other income grew 50% YoY to INR 2,464 crores in Q1FY27.
Show source
I'm happy to report another record quarter of earnings with total revenue from operations growing 32% YoY to INR 8,277 crores, and EBITDA excluding forex and other income growing at strong 50% YoY to INR 2,464 crores.
- U.S. business recorded sales of USD 366 million, 30% higher YoY in constant currency terms in Q1FY27.
Show source
U.S Business During the quarter, the U.S. business recorded sales of USD 366 million, 30% higher YoY in constant currency terms.
- India business recorded sales of INR 2,380 crores, growing 13.9% YoY in Q1FY27.
Show source
Page 4 of 17 August 7, 2026 India Region During the quarter, the India business recorded sales of INR 2,380 crores, growing 13.9% YoY.
- Respiratory segment grew 6.9% in Q1FY27 against category growth of 11.3%, resulting in lower growth.
Show source
This is offset by lower growth in Respiratory segment which grew 6.9% as against category growth of 11.3%.
- In-licensed products accounted for around 6% in Q1FY27, similar to FY26 levels.
Show source
The share of in-licensed products in this quarter is around 6%, similar to the FY26 levels.
- Other Developed Markets, Europe, Canada, and Australia recorded sales of INR 1,149 crores, growing 48% YoY and accounting for 14% of total sales in Q1FY27, up from 11% in FY26.
Show source
Other Developed Markets For the quarter, our Other Developed Markets, Europe, Canada, and Australia recorded sales of INR 1,149 crores growing 48% YoY and accounting for 14% of our total sales, an increase from 11% in FY26.
- Other Operating Income was INR 60 crores in Q1FY27, compared with INR 105 crores in Q1FY26, a 43% YoY decrease primarily on account of lower export benefits from the PLI schemes during the quarter.
Show source
P&L Going on to the P&L. Other Operating Income Other Operating Income at INR 60 crores as against INR 105 crores in Q1FY26, has decreased 43% YoY.
- Gross margin was 74.6% in Q1FY27, up from 71.3% in Q1FY26; the 330 basis points YoY improvement was driven by better product mix, higher profitability in India, increased volumes, cost improvements, and efficiencies undertaken over the last several quarters.
Show source
This quarter was at 74.6% up from 71.3% in Q1FY26 last year.
- Employee Benefit Expenses were INR 1,383 crores, 28% higher than INR 1,083 crores in Q1FY26, and were 16.8% of sales versus 17.6% in Q1FY26; the change was largely attributable to regular annual increments and business growth during Q1FY27.
Show source
Employee Benefit Expenses For the quarter, Employee Benefit Expenses stood at INR 1,383 crores, increasing 28% YoY from INR 1,083 crores in Q1FY26, translating to 16.8% of sales versus 17.6% last year.
- Manufacturing and other expenses were INR 2,341 crores, approximately 28.5% of sales in Q1FY27 compared with 28.7% in Q1FY26; expenses were higher mainly due to higher business volumes, higher SG&A expenses from field force expansion, license fee payments, and part of settlement agreements. Lupin’s consolidated manufacturing and other expenses were INR 23,412 Mn, 28.5% of sales, in the quarter ended June 30, 2026.
Show source
Manufacturing and other expenses Q1FY27 Manufacturing and Other expenses came in at INR 2,341 crores, which translates to approximately 28.5% of sales as compared to 28.7% of sales in Q1 last year.
- R&D was INR 608 crores, 7.4% of sales in Q1FY27, compared with INR 498 crores, 8.1% of sales in Q1FY26.
Show source
R&D R&D at INR 608 crores is 7.4% of sales in Q1FY27, as compared to INR 498 crores at 8.1% of sales in Q1FY26.
- EBITDA excluding forex and other income was INR 2,464 crores in Q1FY27, compared with INR 1,641 crores in the same period last year, an increase of 50% YoY.
Show source
EBITDA EBITDA excluding forex and other income during the quarter was INR 2,464 crores vis-a-vis INR 1,641 crores in the same period last year, an increase of 50% YoY.
- EBITDA margins were 30% in Q1FY27 compared with 26.6% in the same period last year, an increase of 340 basis points.
Show source
Margins were 30% vis-a-vis 26.6% last year in the same period, an increase of 340 basis points over the last year.
- Depreciation and amortization was INR 453 crores in Q1FY27 compared with INR 299 crores in the corresponding quarter last year; the increase was due to higher amortization of settlement agreements.
Show source
Depreciation Depreciation & amortization at INR 453 crores is compared to INR 299 crores in corresponding quarter last year.
- Effective tax rate was 29.8% in Q1FY27.
Show source
ETR The effective tax rate stood at 29.8% for the quarter.
- ROCE was 29.5% as at the end of Q1FY27, compared with 28.4% as at end of FY26.
Show source
ROCE ROCE for the company translates to 29.5% vis-a-vis 28.4% as at end of FY26.
- Adjacencies contribute an overall hit of about 1% to 1.5%.
Show source
Ramesh Swaminathan : Overall about 1% - 1.5%.
- U.S. business growth in Q1FY27 was driven by higher volumes in base business, offset by additional competition in Mirabegron.
Show source
This growth has been driven by higher volumes in base business, offset by additional competition in key products like Mirabegron.
- GIB business in India had lower tender sales in Q1FY27.
Show source
This is offset by lower tender sales in our GIB business in India.
- Staff and other expenses have increased because of increments, recruitment based on business needs including in the India region, and an Fx impact versus the previous year.
Show source
Ramesh Swaminathan: The cost lines are essentially because of increments, then based on the needs of business, including India region, we have also been recruiting people.
- Some of Lupin's adjacencies are still making losses, though Lupin expects those losses to come down over time.
Show source
Some of them are still making losses, though, of course, I think it will come down over time.
- OTC and CDMO businesses are still loss making and are impacting EBITDA margins and overall EPS; Lupin expects this to be a thing of the past in quarters to come.
Show source
But I think you would do well to remember that all of these are at this stage loss making and therefore is impacting EBITDA margins and of course, our overall EPS at this stage.
- Other Developed Markets, Europe, Canada, and Australia accounted for 14% of its revenues in Q1FY27, up from 11% in FY26. Replaced by a later filing.
- R&D spend was 7.4% of sales in Q1FY27. Replaced by a later filing.
- Core prescription business grew 15.1% YoY in Q1FY27 against IPM growth of 13.5%, translating to 1.1x IPM growth. Replaced by a later filing.
Money and capital
- Operating Working Capital was INR 8,260 crores as of 30 June '26, compared with INR 7,132 crores as of 31 March '26, representing 90 days of net working capital compared with 87 days recorded earlier.
Show source
Page 6 of 17 August 7, 2026 Balance sheet Operating Working Capital The Operating Working Capital was INR 8,260 crores as of 30 June '26 as compared to INR 7,132 crores as of 31 March '26, which translates to 90 days of net working capital as compared to 87 days recorded earlier.
- Net cash stood at INR 2,831 crores as of 30 June, compared with INR 4,636 crores as of 31 March quarter, largely due to closure of the VISUfarma acquisition.
Show source
Net Cash Net cash stood at INR 2,831 crores as of 30 June vis-a-vis INR 4,636 crores as of 31 March quarter, largely due to closure of our VISUfarma acquisition .
- The company will make a small commercial investment in the U.S., in particular for Apixaban 505(b)(2).
Show source
We are going to make a small, but commercial investment, in particular in the U.S., even for the 505(b) (2) of Apixaban.
What it expects ahead
What management expects
- The company expects its U.S. business to be in the USD 1.1 billion to USD 1.2 billion range for the full year, aided by growth in base business, injectable launches, and Pegfilgrastim contribution offsetting additional competition in Mirabegron and Tolvaptan during the year.
Show source
For the full year, we expect the U.S. business to be in the USD 1.1 billion to USD 1.2 billion range, aided by growth in base business, our injectable launches, and contribution from Pegfilgrastim offsetting the additional competition in products like Mirabegron and Tolvaptan during the year.
- The company expects to launch 50 plus products in the U.S. in the next three years, including 10 exclusive first-to-files, five biosimilars, and two to three 505(b)(2)s.
Show source
In the next three years, we expect to launch 50 plus products in the U.S. with 10 exclusive first -to-files, five biosimilars, as well as two to three 505(b)(2)s. We are planning to file more than 15 products this year, including at least seven in the Respiratory segment.
- The company plans to file more than 15 products in the U.S. this year, including at least seven in the Respiratory segment.
Show source
In the next three years, we expect to launch 50 plus products in the U.S. with 10 exclusive first -to-files, five biosimilars, as well as two to three 505(b)(2)s. We are planning to file more than 15 products this year, including at least seven in the Respiratory segment.
- The company targets novel proprietary products contributing one third of its India revenues in the next 10-year timeframe.
Show source
We have set ourselves a target of novel proprietary products contributing one third of our India revenues in the next 10-year timeframe.
- The company will start seeing launches from its 505(b)(2) pipeline this fiscal year, with launches ramping up in the next two years.
Show source
We've also evolved a strong 505( b)(2) pipeline in the last couple of years, and we'll start seeing product launches this fiscal year and ramping up in the next two years.
- The company reiterated guidance of high single-digit revenue growth for the organization with EBITDA margins of around 25% during FY27.
Show source
We would like to reiterate our earlier guidance of high single-digit revenue growth for the organization with EBITDA margins of around 25% during the year.
Show 35 more statements
What management expects
- The company anticipates its U.S. business to revert to its growth trajectory from FY28, largely led by a rich pipeline including exclusive first-to-files, biosimilars, and 505(b)(2) products.
Show source
However, we anticipate the business to revert to its growth trajectory from FY28 largely led by a rich pipeline of products including exclusive first-to-files, biosimilars and 505(b)(2) products.
- The company expects R&D to be around 8% for the full year.
Show source
For the full-year, R&D is expected to be around 8%.
- The company expects EBITDA margins to be around the 25% mark for the full year.
Show source
For the full year, as indicated by Vinita, we expect EBITDA margins to be around the 25% mark.
- The company expects its effective tax rate to be in the region of 27% - 28% for the full-year.
Show source
For the full-year, however, we expect it to be in the region of 27% - 28%.
- The company expects revenues to be anywhere between USD 250 million to USD 280 million a quarter over the next couple of quarters.
Show source
We expect revenues to be anywhere between USD 250 million to USD 280 million a quarter over the next couple of quarters.
- EBITDA margins would be in the range of 24% to 25%, as price increases following cost increases because of geopolitical tensions affect gross margins; the first quarter was less affected because Lupin carried forward inventories.
Show source
So, I think we are being a little more cautious when you speak about the fact that the EBITDA margins would be in the range of 24% to 25%.
- Goal for India is USD 1 billion or one-third of its business from innovative products, an aspiration for the next 10 years; this means developing 10 to 15 products every year.
Show source
The goal of USD 1 billion or one -third of our business to come from innovative products is an aspiration for the next 10 years.
- The company is looking at 60 to 70 launches of innovative products over the next 10 years; in the next three years, not even three or four launches would be truly innovative products.
Show source
Nilesh Gupta: So, over a period of the next 10 years, we're looking at 60 to 70 launches of the innovative products.
- The company is sizing up Apixaban 505(b)(2) as a material brand and has a goal date of September for approval; it hopes to receive approval in September, is building launch quantities simultaneously, expects material commercial quantities to start in January '27 calendar year, and expects to launch in the summer, hopefully 10 to 12 months before others enter.
Show source
And we expect to start having material commercial quantities start in January '27 calendar year, and we would expect somewhere in the summer that we should launch and hopefully get 10 to 12 months before others enter.
- The company expects Other Developed market and EMEA to grow between 10% and 20% over the next couple of years, with some years higher than others.
Show source
Vinita Gupta: We are looking at potentially double -digit growth, in some years., higher than others, but anywhere between 10% to 20% over the next couple of years.
- The company plans to launch 20+ products in India in FY27.
Show source
We have launched around seven products in Q1FY27 and plan to launch about 20 products in FY27, vis-a-visa 15 products which we have launched in FY26.
- The company expects the U.S. business to get back to its growth trajectory from FY28 onwards, with its initiatives helping that recovery.
Show source
We believe that all these initiatives should help in the U.S. getting back to its growth trajectory from FY28 onwards.
- The company expects to launch vial and oral dosage forms of Semaglutide in the second half of this fiscal year.
Show source
This segment is poised for continued healthy growth with the expected launch of vial and oral dosage forms of Semaglutide in the second half of this fiscal year.
- The company anticipates some moderation in performance during the remainder of FY27, especially in the U.S. because of increased competitive intensity on its two major products.
Show source
Page 3 of 17 August 7, 2026 In conclusion, while we have started the year on a strong note, as indicated earlier, we anticipate some moderation in performance during the remainder of the year, especially in the U.S. from increased competitive intensity on our two major products.
- U.S. sales will be impacted by competition in Mirabegron and Tolvaptan this year.
Show source
Whilst we continue to benefit from our differentiated strategy on focusing on complex products, as indicated in our earlier interactions, the overall sales in the U.S. will be impacted by competition in key products like Mirabegron and Tolvaptan this year.
- The company expects Mirabegron to have a full quarter impact from Q2 onwards after it saw pressure in the first quarter.
Show source
Mirabegron has already seen pressure in the first quarter, and we expect that to be a full quarter impact from Q2 onwards.
- The company expects its baseline respiratory business to be stable as Dulera®, its nasal spray products in the next year, and new products Respimat and others come to market.
Show source
So , we would expect that the baseline should be stable as Dulera®, our nasal spray products in the next year, and then the new products, Respimat, as well as others come to market .
- The company expects other countries to follow a model similar to France if that model works there, making the generic and biosimilar sides of the business more substitutable to afford innovation and efficient access to medicines.
Show source
And I think if that model works for France, we will see very soon the other countries following a similar model to be able to afford innovation, while making the generic side and the biosimilar side of the business more substitutable to be able to get efficient access to medicines.
- The company is optimistic that Europe will increasingly become a more important geography for the company, given its portfolio of respiratory products, biosimilars, ophthalmology biosimilars and specialty portfolio.
Show source
We are very optimistic, very hopeful that Europe is going to increasingly become a more important geography for Lupin for certain, just given our portfolio of respiratory products, biosimilars overall, as well as the ophthalmology biosimilars, as well as the specialty portfolio.
- New measures in France will likely enhance biosimilar adoption and ease market access for Lupin.
Show source
In France, new measures that will likely enhance biosimilar adoption and ease market access for us, all of which gives us this optimism on the biosimilars front .
- The company expects a significant year of filings for respiratory MDI products.
Show source
On the MDI front, it's going to be a significant year of filings on the respiratory MDI products.
- The company cleared a device challenge for Respimat Spiriva and will file the product this year.
Show source
Page 13 of 17 August 7, 2026 And then on the Spiriva front, on the Respimat Spiriva, there was more of a device challenge that we faced & that now that we have cleared it and we'll file the product this year.
- The company will seek to leverage Coral Springs domestic manufacturing in the U.S. for expedited review of products as the administration focuses on getting more onshoring of products in the U.S.
Show source
We'll also want to leverage the Coral Springs domestic manufacturing in the U.S. for expedited review of these products that the administration is focused on to get more onshoring of products in the U.S. Kunal Dhamesha: Just one aspect of this, let's say, if you have an MDI line for one product, can the capacity become fungible for another MDI, or it does not?
- The company expects approval of the Rx Fluticasone nasal spray this year and the OTC Fluticasone nasal spray in FY28; it filed both Rx and OTC.
Show source
We would expect the Rx approval to come in this year and OTC in FY28 .
- The company expects volatility between quarters, but cannot speak to its magnitude at this stage.
Show source
Ramesh Swaminathan: There will be volatility between quarters, for sure.
- The company expects its Diagnostics business to break even next year.
Show source
It will be break -even, for sure.
- The company expects Xywav® to be a FY33 product.
Show source
Page 15 of 17 August 7, 2026 Vinita Gupta: It's a FY33 product for us .
- The company expects margins in Other Developed market and EMEA to continue to expand as its business grows in scale, with additional portfolio and pipeline expansion.
Show source
And with the additional portfolio, as well as the expansion with the pipeline, we expect margins to continue to expand as well .
- The company is looking for its complex generics portfolio to double over the next three to five years.
Show source
Overall, we are looking at our portfolio from the complex generics doubling over the next three to five years.
- Team will use learnings from the last couple of years to expedite filings and potential approvals across its respiratory platforms. Replaced by a later filing.
Show source
So, I'd say different level of complexity across the different platforms, but a lot of learnings over the last couple of years that the team will leverage to be able to expedite the filings as well as potential approvals.
- The company expects the FDA to expedite approvals for its products that are either CGT or have no competition in the marketplace. Replaced by a later filing.
Show source
Given that these products are either CGT or have no competition in the marketplace, the FDA is also looking to expedite these approvals.
- The company believes its Diagnostics business will do very well next year. Replaced by a later filing.
Show source
Next year, for example, we believe the Diagnostics business will do very well.
- The company expects to maximize its biosimilars business. Replaced by a later filing.
Show source
Vinita Gupta: We expect to really maximize the biosimilars business .
- The company is looking at a potential expansion in margins from the inherent growth of its pipeline and an increase in complexity. Replaced by a later filing.
Show source
We are looking at a potential expansion in margins.
- The company will make investments to maximize opportunities from its pipeline. Replaced by a later filing.
Show source
Of course, we'll make investments as well, as I mentioned, in maximizing these opportunities.
What it is building and selling
Projects and capacity
- The company has filed Dulera® and expects to file the ANDA for the Ellipta franchise later this fiscal year; it expects to be in a position to file Respimat this fiscal year.
Show source
So very pleased to get the Ellipta franchise also started from a pipeline perspective, and we would expect to file the ANDA later this fiscal year.
- The company was successful with a pivotal PK on B reo®.
Show source
We also have been successful with a pivotal PK on B reo®.
- The company filed the Luforbec ® new propellant in Europe in the last quarter, and multiple pipeline programs for Europe are making progress.
Show source
We have green propellants, the Luforbec ® new propellant filed in Europe in the last quarter in fact, and multiple pipeline programs also making progress for Europe.
- Respiratory products are being developed at facilities in India and Coral Springs.
Show source
In addition to that, a number of these products are out of India, some out of our facility in Coral Springs.
Demand and pricing
- Albuterol market share was 16%, and the market had stabilized based on the supply situations from different competitors.
Show source
It has the 16% share, and the relative positions of competition are kind of stabilized based on the supply situations from the different competitors.
- In Germany, Ranibizumab and Aflibercept are no longer part of the AOK tenders, creating a branded opportunity for Lupin's biosimilars.
Show source
And even in Germany, on the one side, you see the increase in rebate on a part of our portfolio, but in others, for example, in our biosimilars, in particular for Ranibizumab and Aflibercept, we are finding that it's not part of the AOK tenders anymore.
Show 10 more statements
Demand and pricing
- The company has recently noticed France doubling down on biosimilars, given the importance of biologics LOE.
Show source
We are starting to see, like, in countries like France, we have recently noticed that they are really doubling down on biosimilars, just given how important the biologics LOE is.
- Pricing on Lupin's products in Europe is fairly stable.
Show source
Vinita Gupta: In Europe, the pricing on our products is fairly stable .
- In Germany, Lupin's ophthalmology biosimilar products are not part of tenders, creating more of a branded opportunity.
Show source
And like I mentioned, we're also starting to see new developments, like in Germany, these products are not part of tenders, so more of a branded opportunity on the ophthalmology front.
Segments
- Chronic segment accounted for around 67% of its portfolio in Q1FY27, up from around 65% in FY26, and the company targets increasing that share to 70% in the next five years.
Show source
The Chronic segment accounts for around 67% of our portfolio, up from around 65% in FY26, and we have set ourselves a target to increase the share to 70% in the next five years.
- Tiotropium, Albuterol and Xopenex® together account for over 20% of Lupin's U.S. base business.
Show source
Vinita Gupta: In the base business, I'm just going by memory here, it's over 20% right now, Tiotropium, Albuterol as well as Xopenex®.
- The company had over 50 active products in its pipeline, with near-term emphasis on Respiratory, Complex Injectables and Biosimilars.
Show source
We have over 50 active products in the pipeline with near-term emphasis on respiratory, complex injectables, and biosimilars.
- The company launched Empagliflozin in Brazil and South Africa and expects to launch Semaglutide in South Africa later this year, establishing a presence in the diabetes metabolic space in emerging markets with Dapagliflozin as a strong start.
Show source
As mentioned earlier, we are starting to establish a presence in the diabetes metabolic space in the emerging markets, with Dapagliflozin serving as a strong start, and the launch of Empagliflozin in Brazil and South Africa, as well as Semaglutide in South Africa later this year.
- The company got a positive PK on its first product on the Ellipta® platform after working on it for multiple years.
Show source
We've been working on it for multiple years and I'm very pleased to finally be able to get a positive PK on the first product.
- The company is working on getting Trelegy® right and will apply learnings from Breo® to that product.
Show source
Now, the next major is getting T relegy® right which our team is working upon and they're going to apply the learnings they have from B reo® onto that product.
- Digital business is evolving extremely well. Replaced by a later filing.
Show source
Our Digital business is evolving extremely well.
Risks, rules and outside factors
Risks and disputes
- The company submitted its responses regarding the Pithampur Unit Il facility and remains on track with its remediation efforts. Replaced by a later filing.
Show source
With regards to Pithampur Unit Il facility, we have submitted our responses and remain on track with our remediation efforts.
- The company is closely monitoring potential headwinds from an uncertain geopolitical environment. Replaced by a later filing.
Show source
We are closely monitoring the potential headwinds from an uncertain geopolitical environment as well.
Rules and policy
- The company received EIRs with VAI status from U.S. FDA for its Ankleshwar and Somerset sites during Q1FY27.
Show source
Switching to compliance, we received EIRs for Ankleshwar and Somerset with VAI status from U.S. FDA for both sites during the quarter.
Everything else said on the call
Group structure
- The company began consolidating VISUfarma in its financials in Q1FY27.
Show source
I would like to highlight that we have begun consolidating VISUfarma in our financials from this quarter.
Other
- USD 100 plus billion worth of biosimilars go off patent over the next five to 10 years.
Show source
Right now, it's like USD 100 plus billion worth of biosimilars that go off patent over the next five to 10 years.
- R&D expenditure is at least ahead above the competition. Replaced by a later filing.
Show source
But we would also do well to understand that our R&D expenditure is at least ahead above the competition, firstly.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Damayanti Kerai: My second question is, if you can update us on some of the key launches or key products in injectables and respiratory space, which will be meaningful from your U.S. sales perspective?
Answer, vinita gupta
Vinita Gupta: So, there are multiple products in the biosimilars, injectables, and respiratory front over the next couple of years. In FY27 itself, we have yet to launch Pegfilgrastim that is going to be an H2 product for us. We expect it to contribute very nicely into the second half. Then we have a 505(b)(2) Dalbavancin injectable that is going to be a good size product for ourselves as well. And nasal sprays like Fluticasone nasal Page 7 of 17 August 7, 2026 spray, as well as injectables, Sugammadex, Epinephrine, Raltegravir, where we have exclusive first-to-file, Eribulin injection, which is all FY27. Then FY28, full-year impact of Pegfilgrastim. We have Diazepam nasal spray, Epinephrine nasal spray, as well as Apixaban 505(b)(2).
Answer, vinita gupta
That is starting to look like a material opportunity for us. We're still sizing it up, but it is looking fairly interesting for us. Then iron sucrose injectable and Saxenda®. We have Ivacaftor exclusive first-to-file, Midazolam nasal spray, and they're just a few of the products. We have other nasal sprays as well as injectables in the pipeline that we'll expect to bring to market in FY28. And then I'd say that in FY29, we should have more biosimilars, Aflibercept, Pegfilgrastim on body injector. Dulera is expected.
Answer, vinita gupta
Hopefully we can get it in FY28, but if not, for certain in FY29 on the market. And depending on what transpires from a P4 standpoint, we would expect Spiriva Respimat®. We've made good progress on that front; we expect to file it in this fiscal year. We should, subject to what happens with the brand, the P4, we could potentially be in the market on the Respimat front as well in FY29.
Question
Damayanti Kerai: Last question is, when you look at the Tiotropium market share, it has been hovering around mid-30s. So, do you have room to improve it further? And if you can talk a bit about your progress in the incremental channels for this product?
Answer, vinita gupta
Vinita Gupta: It's kind of settled at that 38% level. And there is a good balance between what the brand has in terms of share and what we have in terms of market share. So, at this point, it should hover around that level .
Answer, vinita gupta
Vinita Gupta: In Q1, you don't have any additional competition on Tolvaptan. And from Q2 onwards, you will start seeing the impact of Apotex and Teva. We also expect in September, we could potentially have one more entrant. We expect to be a four-player market with Tolvaptan. And we expect the market to grow as well for the molecule, given that it is still 40% generic conversion so far. But given the additional competition, we expect pricing to come down, and obviously also some share re-distribution. So, we expect Tolvaptan to come down over the next couple of quarters.
Answer, vinita gupta
Mirabegron has already seen pressure in the first quarter, and we expect that to be a full quarter impact from Q2 onwards. We expect revenues to be anywhere between USD 250 million to USD 280 million a quarter over the next couple of quarters. Page 8 of 17 August 7, 2026 Shyam Srinivasan: When I look at your full-year margin guidance of about 25% and we did the gross margins of 75% for the current quarter, right?
Question
So, what's a more normalized gross margin, please?
Answer, ramesh swaminathan
Ramesh Swaminathan: It is really going to be a function of how much of Tolvaptan sales and at what realization, the kind of competition that you see out there. And more importantly, the impact of price increases that we have seen in the recent past; post the cost increase that is because of the geopolitical tensions around. So, the first quarter was not so hugely impacted because of the fact that we had inventories that we carried forward, but going forward, we will have to take that into account. So, I think we are being a little more cautious when you speak about the fact that the EBITDA margins would be in the range of 24% to 25%. And obviously, this would be, as a reduction on the gross margins front as well.
Question
Neha Manpuria: I think in one of your previous call, you'd mentioned that despite additional competition coming through, we should be able to defend our market share in Tolvaptan. Do you see that dynamic playing out given that we've been able to gain share over the last few quarters?
Answer, vinita gupta
Vinita Gupta: Yes. We would expect the market share tail to be longer, because of the fact that it's a specialty pharmacy product as well as our REMS program. But we obviously will have to give some share as well to the additional entrants.
Question
Neha Manpuria: In Apixaban, how should we think about the opportunity? You mentioned you're still sizing it up, but how should we think about the 505(b)(2) launch and our ability to take market share in case we launch it in FY28 ?
Answer, vinita gupta
Vinita Gupta: We are looking at the different channels for the product. It's a very large brand, which makes it a very interesting opportunity. But given the time we have, prior to the other gene rics entering the market in FY29, we believe that a very targeted approach around a few channels is going to serve us well. So, we are looking at ways and means of entering, a few of the larger channels through our national accounts’ efforts, as well as some incremental commercial efforts, to be able to get strong access.
Question
Neha Manpuria: Do you think this should be as large as probably, Mirabegron and Tolvaptan was for us? Could this be as large in your view ?
Answer, vinita gupta
Vinita Gupta: It could potentially get there.
Question
Neha Manpuria: Last question on, biosimilars. Let's take a three-year timeframe because you have a couple of launches coming in FY29, how big can the biosimilars piece be for us here as well as in Europe put together? Page 9 of 17 August 7, 2026 Vinita Gupta: Put together, it's a material opportunity for us.
Answer, vinita gupta
The U.S. itself, of course, we have to deliver this year, but it's looking like a very interesting opportunity with Pegfilgrastim. Ranibizumab, we'll have to convert the market. I mean, the market has gone into the other products. I think a little bit of a smaller opportunity compared to Pegfilgrastim, but Ranibizumab looks like a big opportunity for us in Europe , in a few countries direct and also through our partnerships with Sandoz as well as others. Now, with the VISUfarma footprint that we have across the ophthalmology call point, we're going to leverage that as well for Ranibizumab. And then we have Aflibercept coming in FY29, and the Pegfilgrastim OBI . In FY30, calendar year '29, we have Etanercept.
Answer, vinita gupta
So, I think we are looking at biosimilars ramping up in the next three years to a couple of hundred million dollar s scale business across these key markets.
Question
Soorya Patra: My first question is on the respiratory portfolio. How big is the respiratory portfolio contribution to the overall business for Lupin right now? In terms of the U.S. business, what would be its share currently?
Answer, vinita gupta
Vinita Gupta: In the base business, I'm just going by memory here, it's over 20% right now, Tiotropium, Albuterol as well as Xopenex®. So, a little bit more than 20% even. And as we look at our pipeline, we have Dulera® that is filed. We have multiple products that we are now making progress on like, Respimat, we have made significant progress over the last quarter, and we are in a position to file this fiscal year. We also have been successful with a pivotal PK on B reo®. So very pleased to get the Ellipta franchise also started from a pipeline perspective, and we would expect to file the ANDA later this fiscal year. We have green propellants, the Luforbec ® new propellant filed in Europe in the last quarter in fact, and multiple pipeline programs also making progress for Europe.
Answer, vinita gupta
So really pleased with the progress now that we are making on the respiratory pipeline, with MDIs, DPIs, Respimat, Ellipta, as well as green propellants.
Question
Soorya Patra: From the Albuterol side, for which the market share, has to some extent subsided from the level of 19% - 20% to 16% currently, and possibly we have already reached the peak potential of Tiotropium. So here, in the mid -term, till the time that the pipeline products are getting launched in the U.S., is it fair to believe that the respiratory portfolio in the U.S. is likely to remain flattish or kind of moderating like that ?
Answer, vinita gupta
Vinita Gupta: This is hard to predict for certain. But right now, the Albuterol market has stabilized. It has the 16% share, and the relative positions of competition are kind of stabilized based on the supply situations from the different competitors. On Tiotropium, we know how difficult it has been for us . We haven't really heard of any imminent approvals and launches. So , we would expect that the baseline should be stable as Dulera®, our nasal spray products in the next year, and then the new products, Respimat, as well as others come to market . Page 10 of 17 August 7, 2026 Soorya Patra: My next question is on the Europe business, which has been doing great for us, and that is visible even in this quarter.
Question
But I was just going through the kind of a higher rebate policy initiated by Germany, wherein they are kind of doubling the rebate requ irement. What would be your reading about either profitability or pricing pressure what we can see in the European market? Or let's say, if it is Germany, then even if we restrict that policy to Germany, then what implication that the overall Europe portfolio can see because of this?
Answer, vinita gupta
Vinita Gupta: It's very interesting, the dynamics in all of the European countries that we are realizing. And even in Germany, on the one side, you see the increase in rebate on a part of our portfolio, but in others, for example, in our biosimilars, in particular for Ranibizumab and Aflibercept, we are finding that it's not part of the AOK tenders anymore. So, it becomes a nice, branded opportunity. Overall, we are seeing all the major European markets really struggling with the overall healthcare budgets, the overall drug spends budgets, and they are struggling to really bring more innovative products into the fold and not making enough products available for unmet needs for patients. We are starting to see, like, in countries like France, we have recently noticed that they are really doubling down on biosimilars, just given how important the biologics LOE is. Right now, it's like USD 100 plus billion worth of biosimilars that go off patent over the next five to 10 years. So , more incentives for substitution of biosimilars that we have seen to be able to reduce some of the drug spend so that they can make room for innovative products.
Answer, vinita gupta
And I think if that model works for France, we will see very soon the other countries following a similar model to be able to afford innovation, while making the generic side and the biosimilar side of the business more substitutable to be able to get efficient access to medicines. We are very optimistic, very hopeful that Europe is going to increasingly become a more important geography for Lupin for certain, just given our portfolio of respiratory products, biosimilars overall, as well as the ophthalmology biosimilars, as well as the specialty portfolio. We have tremendous headroom to be able to build in Europe .
Show 17 more questions
Question
Soorya Patra: Just last one question from my side regard ing the biosimilars. Two points specifically here. How sizable are these two opportunities, first two product opportunity in the U.S., for us, because Pegfilgrastim or even Ranibizumab, if you consider both are kind of a partner product, and the prices for this product, for biosimilar prices has already corrected to the tune of 85% to 90%. So, considering that, how sizable this could be? And secondly, given the sharp price erosion that has happened already in the U.S. market, how is the European product prices there in biosimilars compared to that of the U.S.?
Answer, vinita gupta
Vinita Gupta: So even with Pegfilgrastim, as I mentioned earlier also the last couple of quarters, we've been pleasantly surprised with the opportunity that we see right now. And of course, we'll want to deliver that in this fiscal year to be able to gain that confidence operationally. But as we look at our partner's Page 11 of 17 August 7, 2026 forecast and what we can do in the current fiscal year, it's a really good size opportunity for Lupin. As I mentioned, I will not size up each and every product, but if I look at the next three years between U.S. and Europe with these three products or so, we have a couple of hundred million dollars worth of opportunity on the biosimilars front .
Question
Soorya Patra: And price difference in U.S. and Europe ?
Answer, vinita gupta
Vinita Gupta: In Europe, the pricing on our products is fairly stable . And like I mentioned, we're also starting to see new developments, like in Germany, these products are not part of tenders, so more of a branded opportunity on the ophthalmology front. In France, new measures that will likely enhance biosimilar adoption and ease market access for us, all of which gives us this optimism on the biosimilars front .
Question
Bino Pathiparampil: Second one in FY28, which is the one you mentioned as sole exclusivity?
Answer, vinita gupta
Vinita Gupta: I mentioned Diazepam, Epinephrine that is two nasal sprays, Ivacaftor is another. And yes, those would be the main ones. Suflave® is another exclusive first-to-file next year.
Question
Bino Pathiparampil: Last question on Spiriva Respimat®. How is the market compared to the DPI?
Answer, vinita gupta
Vinita Gupta: It's moved more towards the Respimat. Bino Pathiparampil: If you could give some rough size idea?
Answer, vinita gupta
Vinita Gupta: We'll get back to you with that. I don't have the exact numbers.
Question
Kunal Dhamesha: The first question is on the India business that you shared, that we are planning to derive one-third of the revenue from innovative products. So, can you elaborate more on this strategy, what would be the kind of required investment here, both from balanc e sheet and P&L perspective? And the usual impression is such in-licensing deals are not very accretive to profitability, right? So, what are we going to do differently? And from therapy perspective, do we stick to our key therapies of cardiac, anti -diabetic, or we look at a more high-growth therapies like oncology?
Answer, nilesh gupta
Nilesh Gupta: So, I think there's three avenues of proprietary products. One is our internal pipeline. So, we're building those internally. Another is in-licensing deals, as you talked. And the other most important and what will be the biggest will be pure innovative NCEs that we would bring to market, products like Bofanglutide that we announced a little while ago, which is now in the clinical development path, and in the next couple of years, we should be able to bring to market. Page 12 of 17 August 7, 2026 So, we've allocated the capital for this. It's purely India.
Answer, nilesh gupta
It's not that expensive from overall licensing or a development perspective. Obviously, you need to have the entire suite of capabilities. So, you do need to have the ability to assess a new chem ical entity at an early stage, do the clinical development and bring it to market. And in a market like India, how do you build ability to do, over a period of time, 30, 40, 50 assets at a time. The goal of USD 1 billion or one -third of our business to come from innovative products is an aspiration for the next 10 years. But I think if you break it down, it basically means to be able to do 10 to 15 products every year. I think it's coming together quite well.
Answer, nilesh gupta
So , in the next three years, we should start bringing those products to market and really build that pipeline. Obviously, key interest would be in our key therapy area, so which are products in respiratory , cardiology and diabetes. From an innovation perspective, obviously, 50% of what you would see as assets would be in areas like oncology, where we're not strong. Then we would cherry pick and we would pick assets that we feel can be really first -in-class, so that it can make a real difference in the market. We've started the journey. I think we've started it with putting strong capability together as well. And we'd love to keep updating you as the pipeline develops.
Question
Kunal Dhamesha: You are suggesting like 80 launches in India in the next three years, right? So how many of that you think would be from this market?
Answer, nilesh gupta
Nilesh Gupta: So, over a period of the next 10 years, we're looking at 60 to 70 launches of the innovative products. In the next three years, a very small fraction, I would say not even three, four of these would be truly innovative products .
Question
Kunal Dhamesha: Given that we have now established track record of selling both DPI & MDI products in U.S., how is it helping us in terms of clearing or like developing the next phase of respiratory products in terms of development cycles in your view? How the development cycles are shrinking and what are some of the learnings, which would help you bring this nex t wave of products to the market efficiently?
Answer, vinita gupta
Vinita Gupta: I'd say that in the different platforms, the complexities are different. On the MDI front, it's going to be a significant year of filings on the respiratory MDI products. I'd say on the Ellipta ® platform, that was likely our most challenging platform. We've been working on it for multiple years and I'm very pleased to finally be able to get a positive PK on the first product. Now, the next major is getting T relegy® right which our team is working upon and they're going to apply the learnings they have from B reo® onto that product. Page 13 of 17 August 7, 2026 And then on the Spiriva front, on the Respimat Spiriva, there was more of a device challenge that we faced & that now that we have cleared it and we'll file the product this year. The follow-on products become easier for us.
Answer, vinita gupta
So, I'd say different level of complexity across the different platforms, but a lot of learnings over the last couple of years that the team will leverage to be able to expedite the filings as well as potential approvals. Given that these products are either CGT or have no competition in the marketplace, the FDA is also looking to expedite these approvals. So, I'm going to look forward to leveraging that. In addition to that, a number of these products are out of India, some out of our facility in Coral Springs. We'll also want to leverage the Coral Springs domestic manufacturing in the U.S. for expedited review of these products that the administration is focused on to get more onshoring of products in the U.S. Kunal Dhamesha: Just one aspect of this, let's say, if you have an MDI line for one product, can the capacity become fungible for another MDI, or it does not?
Question
Kunal Dhamesha: On the Apixaban 505(b)(2). From here, what are the key monitorables for you? And what's the duration advantage that we will have vis-a-vis the generics, which has slated to enter the early part of FY29, I believe?
Answer, vinita gupta
Vinita Gupta: As I mentioned, we are sizing it up, but like material brands, so one first monitorable thing that one can track is the approval. We have a goal date of September. We are hoping that we get approval in September, and then simultaneously we're building up launch quantities. And we expect to start having material commercial quantities start in January '27 calendar year, and we would expect somewhere in the summer that we should launch and hopefully get 10 to 12 months before others enter.
Question
Kunal Dhamesha: Can you share, which plant is it filed from?
Answer, vinita gupta
Vinita Gupta: It's Somerset, that's been cleared recently.
Question
Tushar Manudhane: In the opening remarks, you alluded to Fluticasone nasal spray. What dosages have you filed? And like where are we in terms of the approval process ?
Answer, vinita gupta
Vinita Gupta: We filed both the Rx as well as OTC. We would expect the Rx approval to come in this year and OTC in FY28 .
Question
Tushar Manudhane: All the formulation as well as API being manufactured in -house, or how is it?
Answer, vinita gupta
Vinita Gupta: The formulation is all in-house. The API is not.
Question
Vivek Agarwal: Couple of questions on the cost base. If you look your staff cost and other expenses have gone up meaningfully. So, just if you can help us understand, how to look at these lines going forward, and what is driving these cost lines significantly?
Answer, ramesh swaminathan
Ramesh Swaminathan: The cost lines are essentially because of increments, then based on the needs of business, including India region, we have also been recruiting people. And there's also an Fx impact, at least, vis-à-vis the previous year.
Question
Vivek Agarwal: Is it fair to understand right, before you launch a major product that is Apixaban and in between a couple of major products, you are seeing incremental competition, there may be a few quarters where your EBITDA margin can fall even below 20%?
Answer, ramesh swaminathan
Ramesh Swaminathan: There will be volatility between quarters, for sure. The magnitude is something that we can't actually speak about at this stage. But we would also do well to understand that our R&D expenditure is at least ahead above the competition, firstly. And secondly, we also have the impact of adjacencies and so on, which have been captured. They're still evolving. Some of them are still making losses, though, of course, I think it will come down over time. Next year, for example, we believe the Diagnostics business will do very well.
Answer, ramesh swaminathan
It will be break -even, for sure. And I would say the same thing for other businesses. Our Digital business is evolving extremely well. You could say that for the OTC business and CDMO as well. But I think you would do well to remember that all of these are at this stage loss making and therefore is impacting EBITDA margins and of course, our overall EPS at this stage. But clearly, that would be a thing of the past in quarters to come . Vivek Agarwal : Is it possible for you to quantify what kind of the losses in terms of percentage hit on EBITDA margin these adjacencies are contributing at this point of time ?
Answer, ramesh swaminathan
Ramesh Swaminathan : Overall about 1% - 1.5%. Vivek Agarwal : One product specific question I have. You have a one product, one FTF that is Xywav®. So, is it a FY29, FY30 type of product, or is it like a FY30 or beyond ? Page 15 of 17 August 7, 2026 Vinita Gupta: It's a FY33 product for us .
Question
Saurabh Kapadia: Just one question on the Other Developed market and EMEA. What could be the sustainable growth in this market over the next couple of years? And secondly, with the kind of growth we have seen, how the profitability or the margins in the key market have moved over the last three - four quarters?
Answer, vinita gupta
Vinita Gupta: We are looking at potentially double -digit growth, in some years., higher than others, but anywhere between 10% to 20% over the next couple of years. And the margins just given the scale of the business is growing. We've been subscale so far. And with the additional portfolio, as well as the expansion with the pipeline, we expect margins to continue to expand as well .
Question
Saurabh Kapadia: Do we need incremental investment to be made in any of the geography or any potential inorganic opportunity, which we could seek in any of these specific countries?
Answer, vinita gupta
Vinita Gupta: We expect to really maximize the biosimilars business . We are going to make a small, but commercial investment, in particular in the U.S., even for the 505(b) (2) of Apixaban. And our strategy on the 505(b)(2) front, because we have other products that we have targeted as well, we'll likely make a small commercial investment.
Question
Chintan Sheth: I have a question on the U.S. side of the business where we have put out the numbers in terms of upcoming pipeline of 50 FTFs, 21 exclusive one s. If you can cumulatively provide some indication on the market size of those, and how should one look at monetizing those over the course of next three to five years? You've explained a few of the products already, but if you can cumulatively help us understand how would those numbers can contribute to our incremental revenue in the U.S. markets.
Answer, vinita gupta
Vinita Gupta: Perhaps what we can do is get back to you offline to go through the overall brand revenues and the relative products where we have limited competition. Overall, we are looking at our portfolio from the complex generics doubling over the next three to five years. That along with the fact that we believe with the pipeline we have, we should be able to grow our business in the next three to five years. With the inherent growth out of this pipeline, plus the fact that we are increasing from a complexity standpoint. We are looking at a potential expansion in margins. Of course, we'll make investments as well, as I mentioned, in maximizing these opportunities. But maybe our team can get back to you offline on looking at the overall market size and the like.
Question
Chintan Sheth: To continue?
Answer, vinita gupta
Vinita Gupta: Thank you, friends, for all your questions, and hopefully, we've been able to answer majority of them, but if not, the team will connect and clarify any open questions you have. As I mentioned, we are optimistic about a near-term opportunity as well as long-term opportunity. In the near-term, to be able to navigate our near-term challenges with the opportunities we have from a portfolio perspective, evolving in areas that we've invested for the last many years. In the longer-term, as Nilesh mentioned also, as we evolve innovation, innovation in India, innovation in our specialty business in Europe as well as the U.S., we look forward to delivering long-term growth as well as return for all our stakeholders. Thank you again, and we look forward to connecting with you in the future.
Questions about this call
- When was the Lupin Q1 FY27 earnings call transcript filed?
- Lupin filed the transcript with the exchange on 12 Aug 2026. This page is built from that transcript.
- What does this page list?
- 101 statements from the transcript across 10 topics, 55 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 27 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.